Hepatitis C patients in China will soon be able to access direct-acting antiviral treatments, which can thoroughly cure the liver infection, a senior liver disease specialist said.

"Several DAA medicines are expected to get approval from the top drug authority and enter the Chinese market early next year, which will bring China's hepatitis C treatment in line with international mainstream practices," said Wei Lai, president of the Chinese Society of Liver Diseases of the Chinese Medical Association.

Currently, most Chinese patients are on injection interferon therapy, which takes longer and may cause serious reactions for some recipients.